Healthcare

AstraZeneca and Oracle launch AI collaboration focused initially on Abu Dhabi hypertension care

AstraZeneca and Oracle announced an AI and real-world-data collaboration whose first program will support hypertension care and clinical research in Abu Dhabi with M42.

AstraZeneca and Oracle announced a collaboration combining AstraZeneca’s clinical-development and regulatory expertise with Oracle’s real-world data, cloud infrastructure, and AI-enabled clinical capabilities. The agreement will explore applications across clinical-trial recruitment, earlier diagnosis, drug-safety monitoring, and the use of real-world evidence throughout the medicine lifecycle. The first program is planned for hypertension care and clinical research in Abu Dhabi, in partnership with M42. It is intended to help clinical teams identify patients with uncontrolled hypertension, support guideline-directed care, and improve recruitment into clinical trials. The initiative matters because it connects AI-supported workflows with an active healthcare program in the UAE, while testing whether data and automation can accelerate research and improve access to appropriate care.

Original source: AstraZeneca

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI